HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kai Yuan Selected Research

berbine

1/2022Corrigendum to "Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia" [Eur. J. Med. Chem. 221 (2021) 113522].
10/2021Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kai Yuan Research Topics

Disease

27Neoplasms (Cancer)
01/2022 - 11/2009
13Inflammation (Inflammations)
07/2022 - 10/2015
9Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2022 - 11/2009
7Rheumatoid Arthritis
07/2022 - 01/2014
7Substance-Related Disorders (Drug Abuse)
03/2022 - 07/2011
6Tobacco Use Disorder (Nicotine Dependence)
03/2022 - 06/2015
6Stroke (Strokes)
03/2021 - 01/2020
6Infections
01/2021 - 04/2014
6Hepatocellular Carcinoma (Hepatoma)
08/2019 - 01/2013
5COVID-19
11/2022 - 01/2020
5Lung Neoplasms (Lung Cancer)
01/2022 - 01/2015
5Pain (Aches)
01/2020 - 03/2011
4Arthritis (Polyarthritis)
01/2022 - 01/2018
4Opioid-Related Disorders (Opiate Addiction)
12/2021 - 07/2017
4Breast Neoplasms (Breast Cancer)
07/2020 - 02/2012
4Migraine Disorders (Migraine)
05/2015 - 01/2013
3Focal Nodular Hyperplasia
10/2022 - 01/2017
3Adenocarcinoma of Lung
01/2022 - 02/2018
3Heroin Dependence (Heroin Abuse)
10/2021 - 09/2010
3Mental Disorders (Mental Disorder)
01/2021 - 01/2015
3Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/2019 - 08/2015
3Spinal Tuberculosis (Pott's Disease)
02/2015 - 09/2013
2Carcinoma (Carcinomatosis)
06/2022 - 08/2013
2Hyperlipidemias (Hyperlipidemia)
01/2022 - 10/2021
2Neoplasm Metastasis (Metastasis)
01/2022 - 06/2019
2Carcinogenesis
01/2022 - 02/2020
2Hypersensitivity (Allergy)
10/2021 - 01/2021
2Cerebral Cortical Thinning
12/2020 - 06/2015
2Sleep Initiation and Maintenance Disorders (Insomnia)
04/2020 - 01/2020
2Thrombosis (Thrombus)
10/2019 - 05/2015
2Diabetic Nephropathies (Diabetic Nephropathy)
08/2019 - 12/2016
2Hyperglycemia
08/2019 - 12/2016
2Body Weight (Weight, Body)
12/2016 - 01/2013
2Epilepsy (Aura)
01/2014 - 01/2013
1Osteosarcoma (Osteogenic Sarcoma)
12/2022
1Neuroinflammatory Diseases
11/2022
1Respiratory Insufficiency (Respiratory Failure)
11/2022
1Immune System Diseases (Immune Disorders)
07/2022
1Epistaxis (Nosebleed)
06/2022
1False Aneurysm (Pseudoaneurysm)
06/2022
1Rupture
06/2022
1Hemorrhage
06/2022
1Waardenburg Syndrome (Klein Syndrome)
01/2022
1Prostatic Neoplasms (Prostate Cancer)
01/2022
1Disease Susceptibility (Diathesis)
01/2022
1Major Depressive Disorder (Major Depressive Disorders)
01/2022

Drug/Important Bio-Agent (IBA)

18Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2011
7Heroin (Diamorphine)IBA
11/2022 - 09/2010
7Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2012
5Pharmaceutical PreparationsIBA
12/2022 - 04/2014
5Biological ProductsIBA
01/2022 - 01/2021
52- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA
01/2021 - 01/2020
4VaccinesIBA
11/2022 - 01/2021
4Polyvinyl AlcoholIBA
10/2022 - 01/2017
4Immunoglobulin D (IgD)IBA
03/2022 - 01/2015
4Long Noncoding RNAIBA
01/2022 - 01/2021
3Bleomycin (Blenoxane)FDA LinkGeneric
10/2022 - 01/2017
3EnzymesIBA
02/2015 - 09/2013
2Fentanyl (Sublimaze)FDA LinkGeneric
11/2022 - 11/2019
2berbineIBA
01/2022 - 10/2021
2Transcription Factors (Transcription Factor)IBA
01/2022 - 01/2021
2Competitive Endogenous RNAIBA
01/2022 - 01/2022
2Interleukin-6 (Interleukin 6)IBA
01/2022 - 01/2018
2salicylhydroxamic acid (SHAM)IBA
03/2021 - 08/2012
2NicotineFDA Link
01/2021 - 06/2015
2Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2021 - 01/2018
2Fibrinogen (Factor I)FDA Link
07/2020 - 06/2019
2andrographolideIBA
10/2019 - 12/2016
2DiterpenesIBA
10/2019 - 01/2019
2triptolideIBA
01/2019 - 01/2018
2MicroRNAs (MicroRNA)IBA
10/2017 - 01/2015
2Therapeutic UsesIBA
01/2017 - 08/2012
1Monoclonal AntibodiesIBA
11/2022
1Conjugate VaccinesIBA
11/2022
1EmulsionsIBA
10/2022
1Ethiodized Oil (Ethiodol)FDA Link
10/2022
1PeroxidesIBA
07/2022
1Oxygen (Dioxygen)IBA
07/2022
1MetalsIBA
07/2022
1ZincIBA
07/2022
1IonsIBA
07/2022
1Heparin (Liquaemin)FDA LinkGeneric
06/2022
1KinesinsIBA
02/2022
1Levodopa (L Dopa)FDA LinkGeneric
01/2022
1Dyrk KinasesIBA
01/2022
1Sucrose (Saccharose)IBA
01/2022

Therapy/Procedure

15Therapeutics
06/2022 - 08/2012
3Immunotherapy
01/2022 - 01/2022
3Drug Therapy (Chemotherapy)
01/2022 - 01/2017
3Radiotherapy
01/2022 - 05/2015
3Acupuncture Therapy
01/2014 - 03/2011
2Aftercare (After-Treatment)
01/2022 - 08/2012
2Brain-Computer Interfaces
01/2021 - 01/2020
2Gastrectomy
01/2021 - 01/2019
2Bariatric Surgery
07/2020 - 01/2019
2Moxibustion
08/2019 - 10/2018
2Radiofrequency Ablation
08/2018 - 01/2013
2Acupuncture Points (Acupuncture Point)
01/2014 - 03/2011
1Transcranial Direct Current Stimulation
07/2022
1Stents
06/2022